Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial

Introduction In the HELIOS trial, bendamustine/rituximab (BR) plus ibrutinib (BR-I) improved disease outcomes versus BR plus placebo in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma. Here, we describe the pharmacokinetic (PK) observations, along with modeling to further...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutical research Vol. 36; no. 7; pp. 93 - 12
Main Authors Lavezzi, Silvia Maria, de Jong, Jan, Neyens, Martine, Cramer, Paula, Demirkan, Fatih, Fraser, Graeme, Bartlett, Nancy, Dilhuydy, Marie-Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon, Samoilova, Olga, Goy, Andre, Ganguly, Siddhartha, Salman, Mariya, Howes, Angela, Mahler, Michelle, De Nicolao, Giuseppe, Poggesi, Italo
Format Journal Article
LanguageEnglish
Published New York Springer US 01.07.2019
Springer
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…